BDTX · Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics returned to its clinical-stage biotech profile in Q1 FY2026 after Q1 FY2025's exceptional $70.0 million revenue from the Servier agreement, which the Company assessed under ASC 606 as a customer contract with the upfront payment now fully recognized. This normalization drove revenue to $0.00, a -100.0% change year-over-year, aligning with the absence of further milestone payments and the Company's focus on product candidate advancement.

Operating income swung to a loss of $11.3 million from $54.5 million in the prior year (-120.6% YoY), as expected for a biotech advancing clinical programs. Product candidates in later stages of clinical development generally incur higher costs due to the increased size and duration of trials, contributing to this controlled operating burn. The Company expects to continue generating operating losses for the foreseeable future, with general and administrative expenses anticipated to rise as it supports development and prepares for potential commercialization.

Net income reflected a $9.0 million loss versus $56.5 million profit last year (-116.0% YoY), with diluted EPS at -$0.16 compared to $0.98 (-116.3% YoY). This shift underscores the transition from revenue-driven profitability to investment in pipeline progress. Other income provided some offset, with the increase primarily attributable to higher interest income in 2026 compared to 2025, highlighting effective cash management in a rising rate environment.

Overall, Q1 results reflect strategic focus on clinical advancement post-Servier milestone, with liquidity providing visibility through H2 2028. Investors should note the expected trajectory of losses and prospective G&A growth as commercialization planning ramps up, balanced by the runway supporting key milestones.